论文部分内容阅读
1988年作者监测了41例原发性免疫缺损病人应用静脉注射免疫球蛋白(IGIV),pH4.25(Gramimune-N,Cutter产品)6～15月的肝功,结果无1例证实为非甲非乙型肝炎(NANBH)。本文对其中17例(另1例为新病人)继续每月输给同一制品,剂量400mg/kg体重,并系统地监测了6批制品应用的结果。在14～26月随访期间,监测指标有;血清谷丙转氨酶(SGPT;血清丙氨酸转氨酶,ALT),以及用于监测其他临床情况所需的其他试验(AST、SGOT、LDH、LDH1～5、GGT和HBsAg)。凡连续2次ALT(SGPT)值超过正常值上限2倍以上者诊断为NANBH。经定期(每2～4周)的和输本制品前采血检测,结果仅5例共8次ALT值升高,但均非连续性,且均在正常边缘:1例为3次,各次隔20周,另1例为2次,隔32周,余3例仅各1次。按照前述定
In 1988, the authors monitored the liver function of 41 patients with primary immunodeficiency using intravenous immunoglobulin (IGIV), pH4.25 (Gramimune-N, Cutter product) for 6-15 months. None of the patients were confirmed as non-A Non-Hepatitis B (NANBH). In this paper, 17 of them (the other 1 new patients) continued to be administered to the same product monthly for a dose of 400 mg / kg body weight and the results of six batches of products were systematically monitored. During the follow-up period of 14 to 26 months, the monitoring indicators included serum alanine aminotransferase (SGPT; ALT), and other tests required for monitoring other clinical conditions (AST, SGOT, LDH, LDH 1-5 , GGT and HBsAg). Where two consecutive ALT (SGPT) value more than 2 times the upper limit of normal was diagnosed as NANBH. After regular (every 2 to 4 weeks) and before transfusion of this product blood test, only 5 cases, a total of 8 ALT value increased, but are non-continuous, and are in the normal edge: 1 case of 3 times, each Every other 20 weeks, another 1 case was 2 times, every 32 weeks, the remaining 3 cases only 1 times. In accordance with the foregoing